OnKure Therapeutics (OKUR) Return on Capital Employed (2021 - 2026)
OnKure Therapeutics' (OKUR) quarterly Return on Capital Employed came in at 53.04% in Q1 2026, up 938.0% YoY from 5.11% in Q1 2025, and up 48.14% on a QoQ basis from 102.27% in Q4 2025.
OnKure Therapeutics (OKUR) Return on Capital Employed (2021 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 6 years of Return on Capital Employed data on file, last reported at 53.04% in Q1 2026.
- Quarterly Return on Capital Employed rose 938.0% year-over-year to 53.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53.04% (up 938.0% YoY) and the FY2025 annual result came in at 76.22%, up 772.0% from the prior year.
- Return on Capital Employed grew to 53.04% in Q1 2026, from 102.27% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 19.45% in Q3 2024 to a low of 102.27% in Q4 2025.
- A 5-year average of 55.26% and a median of 53.41% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 3834 bps — and 2025, when it tumbled 7279 bps.
- Tracing OKUR's Return on Capital Employed over 5 years: stood at 49.76% in 2022, then rose by 2 bps to 48.74% in 2023, then plunged by 30 bps to 63.43% in 2024, then tumbled by 61 bps to 102.27% in 2025, then surged by 48 bps to 53.04% in 2026.
- The last three Return on Capital Employed figures came in at 53.04% (Q1 2026), 102.27% (Q4 2025), and 92.24% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | -34.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.07% |
| Mar 31, 2026 | -53.04% |
| Dec 31, 2025 | -102.27% |
| Sep 30, 2025 | -92.24% |
| Jun 30, 2025 | -74.42% |
| Mar 31, 2025 | -62.42% |
| Dec 31, 2024 | -63.43% |
| Sep 30, 2024 | -19.45% |
| Jun 30, 2024 | -29.81% |
| Mar 31, 2024 | -53.41% |
| Dec 31, 2023 | -48.74% |
| Sep 30, 2023 | -57.79% |
| Jun 30, 2023 | -59.76% |
| Mar 31, 2023 | -61.21% |
| Dec 31, 2022 | -49.76% |
| Sep 30, 2022 | -42.08% |
| Jun 30, 2022 | -37.36% |
| Mar 31, 2022 | -32.28% |
| Dec 31, 2021 | -26.15% |
| Sep 30, 2021 | -22.05% |